N8-GP is a glycoPEGylated long-acting recombinant factor VIII (rfVIII) therapy under development by Novo Nordisk for the treatment of hemophilia A. The PEGylation of N8-GP in the B-domain of fVIII protects it from degradation and clearance by proteolytic enzymes, clearance receptors, and immune effector cells, thereby extending its half-life to 18.4 hours. As a longer-acting drug, N8-GP will act as the successor to NovoEight, which Novo Nordisk launched in 2013.
LIST OF FIGURES
8 Figure 49: Datamonitor Healthcare’s drug assessment summary of NovoSeven for hemophilia
12 Figure 60: Datamonitor Healthcare’s drug assessment summary of Nuwiq for hemophilia
LIST OF TABLES 5 Table 1: N8-GP drug profile
7 Table 2: N8-GP Phase III data in hemophilia
13 Table 3: N8-GP sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.